S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$38.53
-2.8%
$42.03
$22.11
$53.18
$2.15B1.49902,396 shs575,466 shs
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Neogen Co. stock logo
NEOG
Neogen
$11.93
-1.7%
$15.52
$11.74
$24.09
$2.58B1.132.14 million shs2.89 million shs
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-2.78%-5.73%-4.84%-3.65%+5.71%
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%+2.21%
Neogen Co. stock logo
NEOG
Neogen
-1.73%-8.23%-21.05%-29.82%-28.95%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.742 of 5 stars
3.41.00.00.02.50.00.0
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
3.222 of 5 stars
3.31.00.00.03.03.32.5
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.80
Moderate Buy$66.0071.30% Upside
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
2.50
Moderate Buy$22.5088.60% Upside
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/A

Current Analyst Ratings

Latest HSKA, CLDX, VIVO, and NEOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
4/15/2024
Neogen Co. stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$19.00 ➝ $17.00
3/22/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
2/27/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $90.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$6.88M313.06N/AN/A$9.08 per share4.24
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Neogen Co. stock logo
NEOG
Neogen
$822.45M3.14$0.89 per share13.36$14.52 per share0.82
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.91N/AN/AN/A-2,054.46%-41.06%-37.65%5/2/2024 (Estimated)
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Neogen Co. stock logo
NEOG
Neogen
-$22.87M$0.011,194.1918.64N/A0.17%3.35%2.30%7/25/2024 (Estimated)
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A

Latest HSKA, CLDX, VIVO, and NEOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/9/2024Q3 2024
Neogen Co. stock logo
NEOG
Neogen
$0.14$0.12-$0.02$0.25$230.01 million$228.80 million    
2/26/2024Q4 2023
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.76-$0.57+$0.19-$0.31$1.20 million$4.13 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
13.87
13.87
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Neogen Co. stock logo
NEOG
Neogen
0.28
3.82
2.66
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Heska Co. stock logo
HSKA
Heska
99.01%
Neogen Co. stock logo
NEOG
Neogen
96.73%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
89.72%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3.70%
Heska Co. stock logo
HSKA
Heska
12.30%
Neogen Co. stock logo
NEOG
Neogen
0.71%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
2.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
16055.90 million53.83 millionOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Neogen Co. stock logo
NEOG
Neogen
2,640216.61 million215.07 millionOptionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable

HSKA, CLDX, VIVO, and NEOG Headlines

SourceHeadline
Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soonVivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon
gizmochina.com - March 24 at 6:33 AM
Vivo V30 Pro review: Flagship-grade imaging system in a slender form factorVivo V30 Pro review: Flagship-grade imaging system in a slender form factor
business-standard.com - March 13 at 2:11 AM
Vivo X Fold 3 Series tipped to outshine iPhone 15 Pro in slimness and weight: ReportVivo X Fold 3 Series tipped to outshine iPhone 15 Pro in slimness and weight: Report
livemint.com - March 11 at 9:30 AM
Meridian Meadows Transitional CareMeridian Meadows Transitional Care
health.usnews.com - February 8 at 6:28 AM
Kendall Ford of MeridianKendall Ford of Meridian
cars.com - January 20 at 12:52 PM
Meridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to SustainabilityMeridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to Sustainability
benzinga.com - November 28 at 3:05 PM
Vivo V29 & V29 Pro coming to India later this month; what we know so farVivo V29 & V29 Pro coming to India later this month; what we know so far
gizmochina.com - September 15 at 5:11 PM
Vivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, MoreVivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, More
news.abplive.com - September 1 at 8:48 PM
Vivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, MoreVivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, More
news.abplive.com - September 1 at 8:48 PM
Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA FlexMeridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex
finance.yahoo.com - July 25 at 7:45 PM
Snapdragon 4 Gen 2 Uses 4nm Platform, Will Power Mid-Range Phones Later This YearSnapdragon 4 Gen 2 Uses 4nm Platform, Will Power Mid-Range Phones Later This Year
droid-life.com - June 26 at 2:14 PM
Mammalian Rho GTPases: new insights into their functions from in vivo studiesMammalian Rho GTPases: new insights into their functions from in vivo studies
nature.com - June 24 at 2:57 PM
Epidemiology, Diagnosis and Treatment ofEpidemiology, Diagnosis and Treatment of
medscape.com - June 11 at 7:57 AM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Future Market InsightsOncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Future Market Insights
fmiblog.com - June 7 at 10:07 AM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Get Insights FMIOncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Get Insights FMI
fmiblog.com - June 2 at 1:18 PM
Rapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028Rapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028
marketwatch.com - May 17 at 10:20 AM
Rapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028Rapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028
marketwatch.com - April 27 at 2:10 AM
Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)
thestreet.com - April 19 at 11:37 PM
Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin AssayMeridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay
markets.businessinsider.com - April 19 at 6:36 PM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033
fmiblog.com - April 7 at 10:46 AM
Former executives at Meridian Bioscience subsidiary facing federal chargesFormer executives at Meridian Bioscience subsidiary facing federal charges
bizjournals.com - April 6 at 6:34 PM
Meridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan DiagnosticsMeridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan Diagnostics
markets.businessinsider.com - April 5 at 8:46 PM
Diagnostics execs charged with concealing lead test flawDiagnostics execs charged with concealing lead test flaw
medtechdive.com - April 5 at 8:46 PM
Meridian Bioscience Stock Hits New 52-Week Low (VIVO)Meridian Bioscience Stock Hits New 52-Week Low (VIVO)
thestreet.com - March 30 at 11:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Celldex Therapeutics logo

Celldex Therapeutics

NASDAQ:CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Heska logo

Heska

NASDAQ:HSKA
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Neogen logo

Neogen

NASDAQ:NEOG
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Meridian Bioscience logo

Meridian Bioscience

NASDAQ:VIVO
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.